Department of Integrative Physiology, University of Colorado Boulder, Boulder, Colorado;, †Intramural Research Program, Laboratory of Cardiovascular Science, National Institute on Aging, National Institutes of Health, Baltimore, Maryland;, ‡Institute of Biomedical and Clinical Sciences, University of Exeter Medical School, Exeter, United Kingdom, §Division of Renal Diseases and Hypertension, University of Colorado Denver Anschutz Medical Center, Aurora, Colorado.
Clin J Am Soc Nephrol. 2013 Nov;8(11):1952-9. doi: 10.2215/CJN.00900113. Epub 2013 Aug 8.
Systolic BP and large elastic artery stiffness both increase with age and are reduced by dietary sodium restriction. Production of the natriuretic hormone marinobufagenin, an endogenous α1 Na+,K+-ATPase inhibitor, is increased in salt-sensitive hypertension and contributes to the rise in systolic BP during sodium loading.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The hypothesis was that dietary sodium restriction performed in middle-aged/older adults (eight men and three women; 60 ± 2 years) with moderately elevated systolic BP (139 ± 2/83 ± 2 mmHg) would reduce urinary marinobufagenin excretion as well as systolic BP and aortic pulse-wave velocity (randomized, placebo-controlled, and crossover design). This study also explored the associations among marinobufagenin excretion with systolic BP and aortic pulse-wave velocity across conditions of 5 weeks of a low-sodium (77 ± 9 mmol/d) and 5 weeks of a normal-sodium (144 ± 7 mmol/d) diet.
Urinary marinobufagenin excretion (weekly measurements; 25.4 ± 1.8 versus 30.7 ± 2.1 pmol/kg per day), systolic BP (127 ± 3 versus 138 ± 5 mmHg), and aortic pulse-wave velocity (700 ± 40 versus 843 ± 36 cm/s) were lower during the low- versus normal-sodium condition (all P<0.05). Across all weeks, marinobufagenin excretion was related with systolic BP (slope=0.61, P<0.001) and sodium excretion (slope=0.46, P<0.001). These associations persisted during the normal- but not the low-sodium condition (both P<0.005). Marinobufagenin excretion also was associated with aortic pulse-wave velocity (slope=0.70, P=0.02) and endothelial cell expression of NAD(P)H oxidase-p47phox (slope=0.64, P=0.006).
These results show, for the first time in humans, that dietary sodium restriction reduces urinary marinobufagenin excretion and that urinary marinobufagenin excretion is positively associated with systolic BP, aortic stiffness (aortic pulse-wave velocity), and endothelial cell expression of the oxidant enzyme NAD(P)H oxidase. Importantly, marinobufagenin excretion is positively related to systolic BP over ranges of sodium intake typical of an American diet, extending previous observations in rodents and humans fed experimentally high-sodium diets.
收缩压和大动脉弹性硬度均随年龄增长而增加,并可通过饮食钠限制来减少。内源性α1 Na+,K+-ATP 酶抑制剂利钠激素 marinobufagenin 的产生在盐敏感型高血压中增加,并导致钠负荷期间收缩压升高。
设计、设置、参与者和测量:假设在患有中度升高的收缩压(139±2/83±2mmHg)的中年/老年人(8 名男性和 3 名女性;60±2 岁)中进行饮食钠限制,将降低尿 marinobufagenin 排泄以及收缩压和主动脉脉搏波速度(随机、安慰剂对照、交叉设计)。本研究还探讨了在 5 周低钠(77±9mmol/d)和 5 周正常钠(144±7mmol/d)饮食条件下,marinobufagenin 排泄与收缩压和主动脉脉搏波速度之间的关联。
尿 marinobufagenin 排泄(每周测量;25.4±1.8 与 30.7±2.1pmol/kg/天)、收缩压(127±3 与 138±5mmHg)和主动脉脉搏波速度(700±40 与 843±36cm/s)在低盐与正常盐条件下均较低(均 P<0.05)。在所有周数中,marinobufagenin 排泄与收缩压(斜率=0.61,P<0.001)和钠排泄(斜率=0.46,P<0.001)相关。这些关联在正常盐条件下仍然存在,但在低盐条件下不存在(均 P<0.005)。Marinobufagenin 排泄还与主动脉脉搏波速度(斜率=0.70,P=0.02)和内皮细胞 NAD(P)H 氧化酶-p47phox 的表达(斜率=0.64,P=0.006)相关。
这些结果首次在人类中表明,饮食钠限制可降低尿 marinobufagenin 排泄,尿 marinobufagenin 排泄与收缩压、主动脉僵硬(主动脉脉搏波速度)和内皮细胞 NAD(P)H 氧化酶的氧化酶活性相关。重要的是,marinobufagenin 排泄与收缩压之间呈正相关,范围为典型的美国饮食中的钠摄入量,扩展了以前在实验性高盐饮食中喂养的啮齿动物和人类的观察结果。